An observational study in Alzheimer Disease, Mild Cognitive Impairment and Subjective Cognitive Decline, sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation. Recruiting at 1 site in Spain. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation — 5 open to participants now, 7 under way, none of them phase 3. Alzheimer Disease · Barcelonabeta Brain Research Center, Pasqual Maragall Foundation.
Among the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, this one is one of 2 that started in 2018, is one of 9 observational ones, and was the 11th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →5 of the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation are open now, in 1 country. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 45–75 · Healthy volunteers
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 60+
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 50–75 · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 45 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2018.
This study's planned enrollment of 400 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 176 across the 6 interventional studies, 250 across the 9 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation is the lead sponsor of 22 studies on the registry; 7 are open to participants now.
4 of the studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02685969Barcelonabeta Brain Research Center, Pasqual Maragall FoundationBrain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants | 2026-12-31 |
| NCT03851523Barcelonabeta Brain Research Center, Pasqual Maragall FoundationLongitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease. | 2026-12-31 |
| NCT07521722Barcelonabeta Brain Research Center, Pasqual Maragall FoundationDIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community | 2027-04-27 |
| NCT07730671Barcelonabeta Brain Research Center, Pasqual Maragall FoundationPENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alzheimer's disease (AD) is the leading cause of dementia and its prevalence is estimated to exceed 100 million affects by 2050, becoming the main public health problem worldwide. AD is considered a clinicopathological entity characterized by a progressive cognitive impairment with affectation of memory and other cognitive domains, which underlies a neuropathological pattern with extracellular accumulation of β-amyloid protein (Aβ) in the form of neuritic plaques, intracellular deposits of tau protein in the form of neuritic strands and neurofibrillary tangles, neuronal and synaptic loss and glial proliferation. Classically, its definitive diagnosis implied the existence of a clinical phenotype compatible with dementia, together with the neuropathological findings characteristic of the disease. More recently, evidence of clinical and biological changes leading to the dementia phase has led to the development of new diagnostic criteria that divide the course of AD into 3 stages: (1) a pre-clinical phase, which would include persons with positive biomarkers with normal cognitive performance for their age and educational level; (2) a phase of mild cognitive impairment (MCI), characterized by cognitive performance lower than expected by age and educational level; and (3) a dementia phase, once cognitive deficits interfere with the activities of daily living.
Recent research has also shed light into the subdivision of each of the above-mentioned stages in distinct phases. For example, the existence of a subjective perception of cognitive decline or a subtle cognitive decline, have been postulated as phases within the AD preclinical stage.
The lack of positive results in the different clinical trials performed to date in patients with AD dementia has redirected the focus of therapeutic strategies towards preventing the development of dementia. For this reason, a detailed characterization of the successive clinical and biological changes that lead to the dementia stage is of vital importance in identifying the persons who could benefit from a possible preventive strategy, as well as the optimal moment to carry out the intervention. The the scientific community, is convinced that intervention aiming to prevent the clinical development of AD dementia must be implemented several years before the first symptoms arise.
In this context, the present project is developed under the hypothesis that subjective cognitive decline (SCD) in individuals with a performance in cognitive tests within normality represents the first symptomatic manifestation of AD. In persons with SCD, the presence of a higher intensity of subjective complaint quantified using a specific subjective complaint questionnaire (SCD-Q) will be associated with lower cognitive performance and a higher rate of conversion to MCI and/or dementia. The relationship between the perception of cognitive decline by the subject and his/her relative will differently vary depending on the stage of the disease: in subjects with progressive cognitive impairment, the subjective perception of cognitive decline will decrease with disease progression whereas the perception of decline will increase with disease progression in their relatives. The degree of perception of cognitive decline throughout the different phases of the disease will be correlated with cognitive and affective patterns as well as with changes in AD biomarkers. These changes will be related to specific brain patterns and abnormal levels of AD biomarkers, which on the other hand will also be present in patients with MCI and mild dementia due to AD.
The present study has two main objectives that are:
Cognitively unimpaired subjects with SCD or MCI/mild dementia individuals
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
No intervention
Subjective Cognitive Decline Questionnaire (my-Cog)
Change in my-Cog score between groups - total score 0-24
Time frame: at inclusion
Subjective Cognitive Decline Questionnaire (their-Cog)
Change in their-Cog score between groups - total score 0-24
Time frame: at inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2018 (actual). Primary completion is estimated for Dec 2026, 106 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 106 months is above that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation